Dr Sarah Cant, Head of Policy and Campaigns at
The Prostate Cancer Charity, spoke to the Daily Mail and the Daily Telegraph, about cabazitaxel,
a new drug which could give men
with advanced prostate cancer two extra months of life.
Cabazitaxel, which was developed by the Institute of Cancer
Research and The Royal Marsden NHS Foundation Trust, is due to be
licensed in Europe in the next few months, after which
the National Institute for Health and Clinical Excellence
(NICE) will assess which NHS patients will have access to it.